Rates and Predictors of Serious Infections in MS and NMOSD Patients treated with Anti-CD20 Therapy

Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs

Comparison of Strategies to Address Hypogammaglobulinemia Secondary to B-cell Depleting Therapies in Neuroimmunology Patients